Shares of the vaccine maker Moderna (MRNA) are up by double digits in after-hours session Tuesday, thanks to a positive clinical update for its experimental coronavirus vaccine mRNA-1273. “Phase 1 data demonstrate that vaccination with mRNA-1273 elicits a robust immune response across all dose levels and clearly support the choice of 100 µg in a prime and boost regimen as the optimal dose for the Phase 3 study,” said Tal Zaks, Chief Medical Officer of Moderna.Following Moderna’s massive gains so far this year, 333% to be exact, is now the right time to recommend investors snap up shares? Jefferies analyst …read more
Source:: Yahoo Finance
